Table 1.
Characteristics of 60 Patients Included on Tissue Microarray
| Non-mutated EGFR (n = 31, 52%) | Mutated EGFR (n = 29, 48%) | P value | |
|---|---|---|---|
| Age (years) | |||
| Median | 70 | 69 | |
| Mean | 68 | 66 | |
| Range | 42–85 | 38–88 | |
| Sex | |||
| Male | 7 (23%) | 7 (24%) | |
| Female | 24 (77%) | 22 (76%) | 1.00 |
| Smoking history | |||
| Former and current | 27 (87%) | 12 (41%) | |
| Never | 4 (13%) | 17 (59%) | 0.0003 |
| Stage at presentation | |||
| I | 13 (42%) | 9 (31%) | |
| II | 5 (16%) | 4 (14%) | |
| III | 9 (29%) | 13 (45%) | |
| IV | 4 (13%) | 3 (10%) | 0.43* |
| Site of tumor | |||
| Primary | 31 (100%) | 27 (93%) | |
| Metastasis | 0 (0%) | 2 (7%) | 0.23 |
| Histology | |||
| Adenocarcinoma | 12 (39%) | 12 (41%) | |
| BAC or adenocarcinoma with BAC feature | 18 (58%) | 16 (55%) | |
| Other | 1 (3%) | 1 (4%) | 1.00† |
| EGFR gene amplification | |||
| Amplified | 5 (16%) | 15 (52%) | |
| Not amplified | 26 (84%) | 14 (48%) | 0.006 |
*
Fisher's exact test result for comparison of stage I versus II, III, and IV.
†
Fisher's exact test result for comparison of adenocarcinoma, BAC, or adenocarcinoma with BAC feature versus other.